← Leaderboards
Satish Kumar Pillai
University Of California, San Francisco
$8,815,181
Attributed
$10,599,955
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,599,955 · 11
By mechanism
R01$6,355,924 · 5
P01$2,241,203 · 2
K01$901,514 · 1
R21$824,289 · 2
R56$277,025 · 1
Top collaborators
- Lishomwa C Ndhlovu7 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Lishomwa C Ndhlovu$30,426,942
- Nisha Bansal$11,641,413
- Ana-Claire Lew Meyer$911,161
- John D Gross$17,630,943
- Nevan J Krogan$73,195,859
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralMediatingSamplingHiv InfectionsMorbidity - Disease RateCellsAntiretroviral TherapyImmuneChronicInterestIntegration Host FactorsInflammationAntiviral AgentsIn VivoMortalityCd4 Positive T LymphocytesNovel StrategiesTechnologyAgingCytokineVirusPlasmaCohortFoundations
Grant awards (37)
Modulation of Galectin-9 to Target HIV Persistence$827,545
R01 · FY2025 · AI · contact PI
Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo$359,333
R01 · FY2025 · AI · contact PI
Modulation of Galectin-9 to Target HIV Persistence$775,391
R01 · FY2024 · AI · contact PI
Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo$360,339
R01 · FY2024 · AI · contact PI
Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo$290,874
R01 · FY2023 · AI · contact PI
Bioinformatics Core$119,063
P01 · FY2023 · AI · contact PI
Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo$277,025
R56 · FY2022 · AI · contact PI
Bioinformatics Core$127,430
P01 · FY2022 · AI · contact PI
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption$395,750
P01 · FY2021 · AI · contact PI
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption$395,750
P01 · FY2020 · AI · contact PI
Effects of Human Galectin-9 on the CNS HIV Reservoir$390,408
R01 · FY2020 · MH · contact PI
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption$395,750
P01 · FY2019 · AI · contact PI
Effects of Human Galectin-9 on the CNS HIV Reservoir$390,387
R01 · FY2019 · MH · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$304,810
R01 · FY2019 · AI · contact PI
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption$395,750
P01 · FY2018 · AI · contact PI
Effects of Human Galectin-9 on the CNS HIV Reservoir$390,406
R01 · FY2018 · MH · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$304,806
R01 · FY2018 · GM · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$82,500
R01 · FY2018 · GM · contact PI
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption$411,710
P01 · FY2017 · AI · contact PI
Effects of Human Galectin-9 on the CNS HIV Reservoir$390,445
R01 · FY2017 · MH · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$304,802
R01 · FY2017 · GM · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$18,560
R01 · FY2017 · GM · contact PI
Effects of Human Galectin-9 on the CNS HIV Reservoir$404,966
R01 · FY2016 · MH · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$304,800
R01 · FY2016 · GM · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$125,000
R01 · FY2016 · GM · contact PI
Effects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV Latency$330,552
R01 · FY2015 · GM · contact PI
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes$197,499
R21 · FY2014 · AI · contact PI
High throughput measurement of envelope gene diversity for an HIV incidence assay$177,242
R21 · FY2014 · AI · contact PI
High throughput measurement of envelope gene diversity for an HIV incidence assay$227,116
R21 · FY2013 · AI · contact PI
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes$222,431
R21 · FY2013 · AI · contact PI
High throughput measurement of envelope gene diversity for an HIV incidence assay$1
R21 · FY2013 · AI · contact PI
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients$118,002
K01 · FY2012 · DA · contact PI
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients$62,072
K01 · FY2012 · DA · contact PI
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients$180,360
K01 · FY2011 · DA · contact PI
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients$180,360
K01 · FY2010 · DA · contact PI
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients$180,360
K01 · FY2009 · DA · contact PI
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients$180,360
K01 · FY2008 · DA · contact PI